The aim of this study was to investigate the methylation status and mRNA expression levels of P15, death-associated protein kinase (DAPK), and suppressor of cytokine signaling-1 (SOCS1) genes in multiple myeloma (MM).
Introduction
Multiple myeloma (MM) is a cancer formed by malignant plasma cells and its compl ex mul tistep pathogenesis has not yet been elucidated. Previous studies have shown that genetic mutations, such as point mutations, translocations or deletions, are important aspects of the pathogenesis of MM (1, 2) . Abnormal chromosomal numbers and structures are detected in approximately 50% of MM patients and thes e anomalies are closely associated with disease prognosis (3, 4) . Increasing attention is being paid to the important rol es of epigenetic changes such as DNA methylation and histone modifications, or abnormal miRNA expression in the pathogenesis of MM (5) . DNA methylation occurs mainly on CpG islands. The methylation of a CpG island, for example in a tumor suppressor gene promoter region, would inhibit transcri ption of this gene, resulting in gene silencing. In tumor tissue, this phenomenon mi ght be much more common than mutations (6) .
It had been found that the inactivation of a series of tumor suppressor genes involved in cell cycle, cell signaling regulation, and apoptosis, was closely related to the occurrence and development of MM. The methylation of tumor suppressor genes involved in the cyclin/cyclin dependent kinase (cdk)/-retinoblastoma (Rb) pathway, the deathassociated protein kinas e (DAPK)/p14RAF/p53 pathway, and the interleukin-6 (IL6) and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling system is reported to play an important rol e in the pathogenesis of MM (7) . P15 gene is a classic tumor suppressor gene and an important member of the cyclin-dependent kinase inhibitor (CDKI) family. Expression of the P15 gene is considered to be closely associated with not only the occurrence of MM, but also with the malignant transformation and disease progression of the plasma cells (8) . DAPK is a calcium/calmodulindependent serine threonine protein kinase, which can activate p53 in a p19ARF-dependent manner, thus inducing apoptosis. Therefore, it is considered to be an independent poor prognostic indicator of diffuse large B-cell lymphoma (9) . The suppressor of cytokine signaling (SO CS) -1 gene is an important member of the SOCS family; it regulates cytokines, but it is also related to a vari ety of immune responses and tumorigenesis in vivo (10) . This study investigated the methylation and mRNA expression levels of P15, DAPK, and SOCS1 genes in MM. The aim was to explore the relationship between the aberrant methylation of tumor suppressor genes and the occurrence, development, and prognosis of MM.
Materials and Methods

Clinical data
The 
DNA extraction and bisulfite modification
Three milliliters of bone marrow samples were extracted from the MM and the control group pati ents and anticoagul ated wi th ethylene diamine tetraacetic acid (EDTA). Ficoll fluid was then used to isolate single karyopl asts for DNA extraction with the whole blood genomic DNA Miniprep kit (Axygen Biosciences, Hangzhou, China). The EZ DNA Methylation-Gold TM Ki t (ZYMO Research Co, CA, USA) was used for the bisulfite conversion of genomic DNA, according to the manufacturer's ins tructions. CpG methyltransferase (M. SssI, New England Biolabs, Inc., MA, USA) was used to prepare the methylated products and the non-methylated positive control.
Methylation specific polymerase chain reaction
According to previous studies (11) (12) (13) , MethPrimer program (http://www.urogene.org/-methprimer/) was applied to design the primers for CpG islands in the upstream 2000 bp from transcription initiation site of target genes. The span of CpG islands was at least 200 bp, with GC content>50% and CpG frequency>0. (14) . The PCR amplification products underwent agarose gel electrophoresis. The image was developed and photographed under ultraviolet light wi th an automatic gel image analyzer, according to the pres ence or absence of specific bands. The results were recorded as positive and negative.
MSP product sequencing
MSP amplification products (50 μl) were stored i n an ice box and sent to Shanghai Invitrogen Co. for automated sequenci ng. The sequencing results were concatenated with DNASTAR software and comparatively analyzed with BiQ Analyzer software.
Reverse transcription quantitative poly merase chain reaction
The total RNA was extracted using TRIzol reagent (Invitrogen Biotechnology Co, Ltd, Shanghai, China). The cDNA was synthesized using TransScript FirstStrand cDNA Synthesis SuperMix cDNA Kit (Shanghai Sangon Biological Engi neering Co, Ltd, Shanghai, China). According to the mRNA complete sequences of P15, DAPK, and SOCS1 genes in Gene Bank, Primer3.0 software (Primer Inc, TX, USA) was used to design the q-PCR primers. The uniqueness of primers was confirmed in NCBI primer blast (http://www. ncbi.nlm.nih.gov/tools/primer-bl ast/). The primers were synthesized by Invitrogen Biotechnology Co, Ltd (Shanghai, China). In the same method, the primer of GAPDH was designed and downstream primer, 5'-AACCATGTAGTTGAGGTCAATGAAG -3. The reverse transcription quanti tative polymerase chain reaction (RT-qPCR) was conducted on CFX96 Touch PCR detection system (Bio-Rad Laboratories, CA, USA), with using Plati num SYBR Green qPCR SuperMix-UDG Kit (Bio-Rad Laboratories, CA, USA). GAPDH was us ed as the internal reference. The PCR steps were as follows: pre-denaturation, 2 min at 50 °C ; denaturation, 2 mi n at 95 °C ; annealing, 15 sec at 95 °C ; elongation, 30 sec at 60 °C . Abov e steps were performed for 40 cycles. The expression amount was pres ented by cycle-threshold. The relative mRNA expression v alues were expressed as fold increas e or decrease relative to GAPDH. 
Statistical methods
The SPSS11.5 s tatistical package was used for statistical analysis. Methylation analysis used the fourfold table χ 2 test; gene expression analysis was described as median±interquartile; the intergroup comparison used the random sample rank sum test for statistical analysis. P≤0.05 was considered significant.
Results
Methylation status
The positive methylation rate of the control group was 0.00% (0/40). The positive methylation rates in the MM patients were as follows: 27.778% (15/54) in CpG islands of the P15 gene promoter region (the corrected χ 2 test showed that the χ 2 v alue was 13.22, P<0.05); 18.52% (10/54) in the DAPK gene promoter region, (χ 2 =7.50, P<0.05); and 16.67% (9/54) in the 3 'end of SO CS1 gene promoter region, (χ 2 =7.37, P<0.05). There was a significant difference in the methylation status e of the MM group promoter regions and the control group promoter regions (P<0.05). Figure 1 shows the electrophoresis of the MSP products.
Sequencing results
The positive MSP amplification samples were sequenced. The sequencing results were concatenated using DNASTAR software and then analyzed with BIQ analyzer software. The presence of methylation in the gene promoter region was determined by a C → T conversion in the s equencing results. The specific methylation sites were then analyzed. The results are s hown i n Figure 2 : 19 nucleotides were methylated at the 5' end of the P15 gene promoter region, and 10 nucleotides were methylated at the 5' end of the DAPK gene promoter region. Theoretically, at the 3' and 5' ends of the SOCS1 gene promoter region, 19 and 22 bases, res pectively, could undergo C → T conversion. However, there were a number of differences in specific base methylation results across different samples, and the methylation frequency was lower than in the positive s amples ; therefore, a full assessment could not be carried out.
Correlations analysis
There was no statistically significant association between the positive methylation rates of the P15, DAPK, and SCOS1 gene promoter regions and pati ent gender or age (≥ 65 years or <65 y ears); stage I + II and stage III; group A and group B; and newly diagnosed patients and recurrent pati ents (P>0.05) ( Table 1-3) .
Reverse transcription-qPCR efficiency
After PCR, the baseline and threshold were set, and the amplification curve and dissolution curve were automatically drawn. At the same time, the standard S1, S0.1, S0.01, S0. 001, and blank control in the reaction plate hole were set, and the s tandard curve was automatically generated. The PCR efficiency was obtai ned. Results showed that, the χ 2 values of P15, DAPK, SOCS1, and GAPDH genes were more than 0.99. The PCR efficiency was 90%-110%, and melting curve had a single peak. This indicated that, the condition of RT-qPCR was well controlled.
Expression of P15, DAPK, and SOCS1 mRNAs
Expression 18±1.28 fold) ; the differrences between the methylated, non methylated, and control groups were not statistically significant (P>0.0167). DAPK mRNA lev els were lower in the initial diagnosis group than in the recurrent group 
Discussion
More and more s tudi es hav e shown (11, 12 )that tumor occurrence and development includes two main mechanisms: 1) nucleotide sequence changes that induce genetic mutations and deletions, namely genetic mechanisms, and 2) base modification changes that result in gene expression level changes, namely epigenetics. The epigenetic changes observed in tumors include DNA methylation, histone modifications, and chromatin remodeling, etc. Epigenetic changes occur in a variety of human tumors, and are associated with tumor occurrence and development; DNA methylation is the most intensively studied epi genetic mechanism. Modern cancer theory considers that, besides genetic structural variations such as mutations and deletions, there exists a third tumor suppressor gene inactivation mechanism, namely methylation. In some cases, it is the only mechanism involved in the inactivation of a tumor suppressor gene. Studies have shown (13, 14) that changes in DNA methylation patterns are closely related to tumorigenesis. Reports (1, 2, 4) regarding abnormal methylation in tumor suppressor gene promoter regions of MM have been mainly focused on genes involved in cell cycle regulation, apoptosis, and cytokine signal transduction, such as P16, P15, P14, E-Cadherin, SHP1, DAPK, O6-methylguanine-DNA methyltransferase, and retinoic acid receptor β. But the methylation rate largely fluctuates among different reports, and its association with clinical features and prognosis were often contradictory. Therefore, further research is necessary.
The P15 gene (also known as cyclin-dependent kinase inhibitor 2B, CDKN2B, inhibits CDK4) is located on human chromosome 9 (9p21). It is an important member of the CDKI family. P15 can inhibit the activity of cyclin-dependent kinases (CDK) 4/6, prev ent the phosphorylation of Rb, and inhibi t the dissociation of transcription factor E2F, thus blocking the cell cycle during the G → S conversion; cells would then be malignantly transformed. Studies have shown that inactivation of the P15 gene through methylation of i ts promoter region in a variety of hematological malignancies such as lymphoma, acute leukemia, and chronic myeloid leukemia (15, 16, 17) . Chim et al (18) reported the hypermethylation of the P15 gene as a common and important event in MM; methylation of the P15 gene promoter region was found in 75% of newly di agnosed patients and 80% of relapsed patients. However, Galm et al (19) concluded the opposite; this study reported that existence of methylation in the P15 gene promoter region of only 1 out of 53 patients, and proposed that the role of P15 gene methylation was overvalued in MM, and it might only be meaningful in acute leukemia.
In this study, the positive methylation rate of the P15 gene promoter region across 54 specimens was 27.78%, while that of the control group was 0. Sequencing of the M SP products revealed that methylation was present at 19 base sites at the 5' end of the P15 promoter region, confirming the existence of aberrant methylation in the P15 promoter region. Our research showed no significant difference in the methylation rates of P15 gene CpG islands among the patients in stage I, II, and III, or in group A and group B, i ndicating that methylation of the P15 gene might be an early event in MM development. There was no significant difference with gender or age, consistent with most other findings (18) .
DAPK is a calcium-calmodulin-dependent seri nethreoni ne protei n kinas e that participates in apoptotic processes medi ated by interferon (IFN)-γ, tumor necrosis factor (TNF), and Fas. In recent years, much attention has been paid to the association between DAPK gene promoter region methylation and cancer (20) . Hypermethylation of the D APK promoter region induces DAPK deficiency and this has been confi rmed as a common phenomenon in Bcell malignancies, such as follicular lymphoma, diffuse large B-cell lymphoma, and Burkitt's lymphoma (21) . Foreign studies (22, 23) found that the positive methylation rate of the DAPK gene promoter region in MM was between 5.9% and 67%; its rate was 18.52% in our study, close to those reported. The positive methylation rate of the control group was 0, indicati ng that methylation of the DAPK gene promoter region does exist in MM.
Esteban B et al (23) found that, although the positive methylation rate of the DAPK promoter region in MM was not high (4/68), it was significantly correl ated with poor prognosis indicators such as high creatinine, calcium, and stage III, and that overall survival was significantly lower than in methylation-negative patients. But this study found that the positive methylation rate of stage I-II tumors was 31.82% (7/22) , and that the rate of stage III tumors was 9.38% (3/32); there was no statistically significant difference between thes e two groups, suggesting that methylation of the DAPK promoter region might be an early event in the pathogenesis of MM. Hatzimichael E et al have compared the positive methylation rates of the D APK promoter region between pati ents with monoclonal gammopathy of undetermined significance(M UGS) and patients with MM; no significant difference was observed, which also indicates that i t may be an early event in the pathogenesis of MM (24) . The positive methylation rate of the DAPK promoter region had no association with gender and age, and there was no statistically significant difference between newly diagnosed patients and relapsed patients. This could indicate that methylation of the DAPK promoter region has nothing to do wi th treatment. It may also be possible that the recurrence its elf was associated with the abnormal methylation of tumor s uppressor genes.
The SOCS family is a family of proteins that was discovered in recent decades. They negatively regulate the JAK/STAT pathway and exert its biological effects. The human SOCS1 gene is located on chromosome 16p13.13. It consists of 1 exon and its full-length is 1776 bp. It encodes 211 amino acids, and is the most s tudi ed member of the SOCS family. Numerous studies have demonstrated that IL6 is the critical growth factor for MM cells, and that SOCS1 is the key that could regulate the expression of IL6 in a negative feedback loop manner (25) .
The positive methylation rates of the SOCS1 promoter region in MM have been reported as 0-74.5% (26) . Among the 54 MM patients in this study, the positive methylation rate of the SOCS1 gene promoter region was 16. 67% (9/54), consistent with the literature. Some authors believe that SOCS1 methylation is an early event in the pathogenesis of MM, and there has been no evidence to date proving its correlation with the progression of MM (27, 28) . Our study also showed that the positive methylation rate of the SOCS1 promoter region had no significant correlation with clinical characteristics such as age, typing, stagi ng, and grouping, or with new or recurrent diagnoses.
In this study, RT-qPCR was performed to study the mRNA expression levels of P15, DAPK, and SOCS1. The resul ts showed that, the expression levels of P15, DAPK, SOCS1 genes mRNA in the bone marrow fluid of MM patients were lower than those in the control group, although the difference was not significant (P>0.05). This indicated that the promoter region methylation of above genes might have some regulatory effect on the expression of the gene, but it was not the main regulatory factor. Toyooka et al (29) found that methylation of tumor s uppressor gene promoter regions and histone deacetylation may downregulate the expression lev els of mRNA, but that it was not the only mechanism. There exists a variety of methods to regul ate gene expression. Besides promoter hypermethylation, the main mechanism of tumor suppressor gene inactivation in human tumors, there may also exist other mechanisms that can lead to the silencing of gene expression, such as gene heterozygosity deletion, or gene homozy gosity deletion (30) . There is not just one method of epi genetic regul ation. DNA methylation regulation also includes histone acetylation, histone methylation, and histone phosphorylation (31). DNA methylation is not the predominant method of gene silencing (6). Jung et al (32) detected 193 myeloma specimens and found that, only the methylation of a few genes, such as interleukin-like growth factor 1 receptor (IGF1R), deleted in liver cancer-1 (DLC1), P16, and interl eukin-17 receptor B (IL17RB), was associated with gene transcription, while the methylation of o ther genes had no association with gene transcription. The reason for this lack of correlation may be that, 5-methylcytosine is necessary but not sufficient for regulating gene expression, and the nature of chromatin formed on a methylated template is what renders it transcriptionally active or inactive. In addi tion, the potential for bias that may have resulted from inadequate specimen size cannot be ruled out. Therefore, an increased s ample number will be needed for further studies.
Conclusion
There existed methylation in the promoter regions of P15, DAPK, and SOCS1 genes in the MM pati ents, and s howed statistically significant difference than the control group (P<0.05), indicating that the methylation in the above genes' promoter regions plays certain roles in the pathogenesis of MM. The positive rates of the methylation i n the abov e genes' promoter regions were not related with gender, age, staging, grouping, and treatment-or-not. In this study, the mRNA expression of P15, DAPK, and SO CS1 genes in the methylation group was lower than the nonmethylation group and the control group; however, the differences showed no statistical significance. This result indicated that the DNA methylation in the gene promoter region mi ght not be the main regulatory factor i nfluencing the mRNA expression of this gene.
